HIPEC After Radical Cystectomy for High Risk Bladder Cancer

Status Completed

Clinical Trial Summary

This is a non-randomized, non-blinded, pilot study administering hyperthermic intraperitoneal chemotherapy with Mitomycin-C in 10 men and women with muscle-invasive urothelial carcinoma of the bladder undergoing radical cystectomy with pelvic lymph node dissection who have risk factors for tumor recurrence.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03514888
Study type	Interventional
Source	Weill Medical College of Cornell University
Contact
Status	Completed
Phase	N/A
Start date	April 19, 2018
Completion date	May 23, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04537221` - Nordic Cystectomy Study III - Transfusion
Completed	`NCT02924480` - Intravenous Lidocaine for Cystectomy Procedures	N/A
Recruiting	`NCT05783271` - Multiparametric Magnetic Resonance Imaging Performance in Detection of Occult Muscle Invasion in Urinary Bladder Cancer
Active, not recruiting	`NCT03702179` - Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach	Phase 2
Completed	`NCT03862105` - Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer	N/A
Recruiting	`NCT02560636` - Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer	Phase 1
Active, not recruiting	`NCT02030574` - Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin	Phase 2
Recruiting	`NCT03844256` - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study	Phase 1/Phase 2
Active, not recruiting	`NCT04134000` - Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)	Phase 1
Terminated	`NCT03498196` - A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT04523025` - Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)
Recruiting	`NCT04523038` - Nordic Cystectomy Study II - Albumin
Withdrawn	`NCT01922232` - MRI and Bladder Cancer Chemotherapy	N/A